Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’s top growth stock picks. On February 18, Eli Lilly and Company (NYSE:LLY) said using Taltz (ixekizumab) together with Zepbound (tirzepatide) ...

Emerging evidence supports the skin microbiome as a promising avenue for precision medicine in the treatment of dermatologic ...

The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...

Women are more likely to experience chronic pain, studies have found, and their pain lasts longer, on average. New research ...

Australia's CSL said on Wednesday it has granted Eli Lilly certain rights to develop and commercialize clazakizumab, an ...

A small but mighty piece of lab equipment, about the size of a cellphone, has arrived at the International Space Station ...

A gene therapy that patients breathe in has been found to shrink lung tumours by inserting immune-boosting genes into ...

"Eli Lilly’s Omvoh achieves 91% Crohn’s steroid-free remission at three years" was originally created and published by ...

Studies show women experience longer-lasting pain than men due to biological differences in immune response and hormones. Research in Science Immunology found men’s testosterone boosts interleukin-10, ...

To all the women who've heard the frustrating "it's all in your head" in response to medical maladies, a new study out Friday ...

CSL Ltd. is out-licensing its interleukin-6 (IL-6) monoclonal antibody, clazakizumab, to Eli Lilly and Co. in a deal that brings CSL $100 million in up-front fees. A CSL spokesperson told BioWorld the ...

Eli Lilly and Company (NYSE:LLY) is included among the 16 Best Dividend Stocks with Rising Payouts. According to a Reuters ...